Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

CTRV - ContraVir Pharmaceuticals Inc.

Previous close
3.58
3.580   100.000%

Share volume: 0
Last Updated: Mon 22 Jul 2019 10:00:00 PM CEST
Pharmaceuticals: Other: 0%

PREVIOUS CLOSE
CHG
CHG%
N/A
0.00
0.00%
This ticker is disabled and data are no longer maintained and up to date.
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
25%
Profitability 40%
Dept financing 22%
Liquidity 6%
Performance 15%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
0   0%
6 Months
0   0%
1 Year
0   0%
2 Year
0   0%
Key data
Stock price
$3.58
P/E Ratio 
N/A
DAY RANGE
$3.58 - $3.58
EPS 
-$88.10
52 WEEK RANGE
$3.52 - $91.00
52 WEEK CHANGE
-$94.63
MARKET CAP 
2.875 M
YIELD 
N/A
SHARES OUTSTANDING 
803.000 K
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
$11,338
AVERAGE 10 VOLUME 
$394,557
AVERAGE 30 VOLUME 
$1,182,789
Company detail
CEO: Robert T. Foster
Region: US
Website: http://www.contravir.com
Employees: 14
IPO year: -
Issue type: Common Stock
Market: NASDAQ
Industry: Pharmaceuticals: Other
Sector: Health Technology

ContraVir Pharmaceuticals, Inc. engages in the development and commercialization of pleiotropic drug therapy for the treatment of chronic liver disease. It focuses on the development of its product candidate CRV431, a cyclophilin inhibitor that targets biochemical pathways involved in the progression of liver disease. The company was founded on May 15, 2013 and is headquartered in Edison, NJ.

Recent news